Article citationsMore>>

Alici, E., Sutlu, T., Bjorkstrand, B., Gilljam, M., Stellan, B., Nahi, H., Quezada, H.C., Gahrton, G., Ljunggren, H.G. and Dilber, M.S. (2008) Autologous Antitumor Activity by NK Cells Expanded from Myeloma Patients Using GMP-Compliant Components. Blood, 111, 3155-3162.
https://doi.org/10.1182/blood-2007-09-110312

has been cited by the following article:

• TITLE: Case Report: Feasibility and Safety of Autologous NK Cell Therapy in Patients with Cancer

  AUTHORS: Supansa Nilubol, Worawit Kitisakronnakorn, Pimjai Naigovit

  KEYWORDS: Natural Killer Cells, NK Cell Therapy, Cancer, Mono-Treatment, Rejuvenation

  JOURNAL NAME: Journal of Cancer Therapy, Vol.12 No.12, December 27, 2021

  ABSTRACT: This study reported two cases of Thai cancer patients, including a 36-year-old female with thyroid cancer of more than 5 years and a 64-year-old male with lung and colon cancers of more than 10 years. The written informed consent was provided for autologous natural killer (NK) cell infusion at the anti-ageing and regenerative medicines clinic. Briefly, the blood was taken from the patient for NK cell count and their cytotoxic activity. Then, the patient’s NK cells were expanded in vitro, characterized and then counted before being delivered to the same patient by a single intravenous infusion. The vital signs and general physical examinations were observed for 2 - 6 hours after the infusion. The patients were discharged if there were no adverse effects. The data showed the increasing number of NK cells and level of cytotoxic activity after the NK cell treatment, compared to the pre-treatment. In addition, the increasing total live cell concentration, as identified by the high percentage of CD56dim/CD16bright cytotoxic NK cells, at day 21 of the NK cell expansion was consistent with the increasing cytotoxic activity of the patients after the treatment. Here, we demonstrated that this autologous NK cell therapy might be feasible; however, the study did not aim to evaluate the anti-cancer effect.